[ET Net News Agency, 15 October 2021] China Medical System Holdings Limited (00867)
said new drug application of the group's innovative drug Tildrakizumab solution for
injection has been accepted by the National Medical Products Administration of the
People's Republic of China.
The product is indicated for the treatment of adults with moderate-to-severe plaque
psoriasis who are candidates for systemic therapy or phototherapy, and has been approved
for marketing in the U.S., Australia, European Union, Switzerland, Japan and Canada. (RC)